PDE5A Inhibitors
Items 1 to 10 of 18 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $180.00 | 13 | |
Tadalafil functions as a selective inhibitor of phosphodiesterase type 5 (PDE5), characterized by its unique binding affinity to the enzyme's active site. This interaction stabilizes the enzyme-substrate complex, leading to a significant reduction in the hydrolysis of cyclic guanosine monophosphate (cGMP). The compound's distinct molecular structure facilitates specific hydrogen bonding and hydrophobic interactions, enhancing its potency and selectivity in modulating cGMP levels within cellular pathways. | ||||||
MBCQ | 150450-53-6 | sc-221874 sc-221874A | 5 mg 25 mg | $74.00 $224.00 | 1 | |
MBCQ acts as a potent phosphodiesterase type 5 (PDE5) inhibitor, exhibiting a unique mechanism of action through its selective binding to the enzyme's allosteric site. This interaction alters the enzyme's conformation, effectively diminishing its catalytic activity. The compound's intricate molecular design promotes specific electrostatic interactions and steric hindrance, which contribute to its enhanced stability and prolonged efficacy in regulating cyclic nucleotide signaling pathways. | ||||||
Ibudilast | 50847-11-5 | sc-203080 | 10 mg | $218.00 | 1 | |
Ibudilast functions as a selective phosphodiesterase type 5 (PDE5) inhibitor, characterized by its ability to modulate enzyme activity through competitive binding at the active site. This compound exhibits unique kinetic properties, allowing for a gradual onset of action. Its structural features facilitate specific hydrogen bonding and hydrophobic interactions, enhancing its affinity for the enzyme. Additionally, Ibudilast's conformational flexibility may influence substrate accessibility, impacting overall enzymatic regulation. | ||||||
4-{[3′,4′-(Methylenedioxy)benzyl]amino}-6-methoxyquinazoline | 150450-42-3 | sc-352371 | 1 mg | $140.00 | ||
4-{[3',4'-(Methylenedioxy)benzyl]amino}-6-methoxyquinazoline acts as a phosphodiesterase type 5 (PDE5A) inhibitor, distinguished by its intricate molecular architecture that promotes selective binding. The presence of methylenedioxy and methoxy groups enhances electron density, facilitating unique π-π stacking interactions with the enzyme. This compound's dynamic conformational changes may optimize its interaction with PDE5A, potentially influencing reaction kinetics and substrate turnover rates. | ||||||
N-Desethyl Vardenafil | 448184-46-1 | sc-208024 sc-208024A sc-208024B sc-208024C sc-208024D sc-208024E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $320.00 $660.00 $1480.00 $2600.00 $3525.00 $10000.00 | 4 | |
N-Desethyl Vardenafil is a selective phosphodiesterase type 5 (PDE5A) inhibitor characterized by its unique structural features that enhance binding affinity. The compound exhibits significant hydrophobic interactions due to its aromatic rings, which stabilize the enzyme-inhibitor complex. Its ability to form hydrogen bonds with key amino acid residues in the active site may modulate enzyme activity, influencing the overall catalytic efficiency and substrate specificity. | ||||||
Thiosildenafil | 479073-79-5 | sc-208435 | 10 mg | $320.00 | 2 | |
Thiosildenafil is a selective phosphodiesterase type 5 (PDE5A) inhibitor distinguished by its unique thiol group, which facilitates specific interactions with the enzyme's active site. This compound demonstrates a notable capacity for conformational flexibility, allowing it to adapt to various binding environments. Its electron-rich structure enhances π-π stacking interactions, contributing to a robust stabilization of the enzyme-inhibitor complex and potentially influencing reaction kinetics. | ||||||
Avanafil | 330784-47-9 | sc-397683 sc-397683A sc-397683B sc-397683C sc-397683D | 10 mg 100 mg 1 g 5 g 50 g | $260.00 $390.00 $490.00 $940.00 $8000.00 | 1 | |
Avanafil is a PDE5A inhibitor used in the research of ED. It is known for its rapid onset of action compared to other PDE5A inhibitors. | ||||||
rac Xanthoanthrafil | 1020251-53-9 | sc-208282 sc-208282A sc-208282B | 5 mg 250 mg 500 mg | $734.00 $4692.00 $8874.00 | ||
Rac Xanthoanthrafil is a selective phosphodiesterase type 5 (PDE5A) inhibitor characterized by its unique structural motifs that promote specific hydrogen bonding and hydrophobic interactions within the enzyme's active site. Its distinct stereochemistry allows for enhanced molecular recognition, leading to increased binding affinity. The compound's dynamic conformational changes facilitate optimal alignment with the enzyme, influencing catalytic efficiency and modulating reaction pathways. | ||||||
(1R,3S)-1-(1,3-Benzodioxol-5-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic Acid Methyl Ester | 171596-44-4 | sc-391567 | 25 mg | $360.00 | ||
(1R,3S)-1-(1,3-Benzodioxol-5-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic Acid Methyl Ester exhibits remarkable selectivity as a phosphodiesterase type 5 (PDE5A) inhibitor. Its intricate molecular architecture enables effective π-π stacking and electrostatic interactions, enhancing its binding stability. The compound's unique functional groups contribute to its ability to modulate enzyme kinetics, influencing substrate accessibility and reaction dynamics within the PDE5A catalytic environment. | ||||||
Vardenafil, Hydrochloride Salt | 224785-91-5 | sc-394434 sc-394434A sc-394434B | 25 mg 100 mg 1 g | $89.00 $206.00 $401.00 | ||
Vardenafil, Hydrochloride Salt is characterized by its unique ability to selectively inhibit phosphodiesterase type 5 (PDE5A) through specific molecular interactions. The compound's structural features facilitate strong hydrogen bonding and hydrophobic interactions, optimizing its affinity for the enzyme's active site. This selective binding alters the enzyme's conformational dynamics, effectively modulating the hydrolysis of cyclic GMP, thereby influencing downstream signaling pathways. | ||||||